gelwoRx™ Dsolve pharmaceutical portfolio extended with three new products
Vilvoorde, October 27, 2022 – PB Leiner is proud to announce that its gelwoRx™ Dsolve pharmaceutical gelatin portfolio has been extended with three new products: Dsolve B, Dsolve P and Dsolve xTRA. The new variants have been specially designed to provide advanced solutions for reduced crosslinking and fast dissolution of soft caps.
Crosslinking is a natural phenomenon that causes a longer dissolution time of soft caps, a lower drug release rate and reduced stability and shelf life of the final dosage formulation. In order to provide a robust answer to crosslinking issues, the gelwoRx™ Dsolve product range has been extended with three new variants: Dsolve B, Dsolve P and Dsolve xTRA.
Variety of raw materials and dissolution performance
The extended portfolio offers a variety of raw materials and dissolution performance. Dsolve P (pig skin) and Dsolve B (beef hide) have been specially designed to reduce crosslinking and show a better dissolution performance compared to the gold standard in soft caps gelatin. Meanwhile, Dsolve xTRA, a bovine bone gelatin innovation, boasts superior performance even when compared to Dsolve, Dsolve P and Dsolve B.
gelwoRx™ Dsolve significantly reduces crosslinking behavior in the capsule’s shell. It promotes a faster dissolution of the capsules and guarantees a rapid filling release, improved stability, and increased shelf life of the final dosage formulations.
Designed for APIs (Rx and OTC) and nutritional supplements.Discover the gelwoRx™ Dsolve portfolio